BSE · 532384
Tyche Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹73 Cr with net profit ₹12 Cr — a 17.02% net margin, versus 16.23% the period before.
Shareholding
As of 2026-06-30
- Promoter61.97%
- Public38.03%
6,786 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.49× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #19 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,654 Cr | 274.97 | 12.31 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,068 Cr | 205.48 | 16.37 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,271 Cr | 118.83 | 13.5 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,568 Cr | 129.46 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,753 Cr | 67.98 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.8 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,730 Cr | 189.21 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,264 Cr | 250.08 | 9.25 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 148.95 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.82 | 3.27 | 17.67% | 13.66% |
| Tyche Industries Ltd.(this company) | ₹124 Cr | 17.87 | 0.89 | 4.94% | 12.9% |
AI analysis
AI-generated · google/gemini-2.5-flashTyche Industries Ltd. is listed on the Indian markets with a market capitalization of Rs 132 Cr. It reported revenue of Rs 72.89 Cr and a profit margin of 12.9%. The company's EPS stands at 6.77, and its book value is Rs 137.05. The promoter holding is 61.9658%.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Promoter holding is 61.9658%, demonstrating a significant stake.
- +The return on equity (ROE) is high at 493.9%.
Negatives
- −Revenue has declined from Rs 80.21 Cr in Mar 2023 to Rs 72.89 Cr in Mar 2025.
- −Net profit has decreased from Rs 14.17 Cr in Mar 2023 to Rs 12.41 Cr in Mar 2025.
- −Annual EPS has declined from 19.35 in Mar 2021 to 12.2 in Mar 2025.
- −The company's quarterly results are only available up to Mar 2026, with no more recent data.
Financial performance
The company's revenue was Rs 82.98 Cr in Mar 2021, and declined to Rs 66.42 Cr in Mar 2022. It then increased to Rs 80.21 Cr in Mar 2023, before decreasing to Rs 75.43 Cr in Mar 2024. In the latest available annual period (Mar 2025), revenue was Rs 72.89 Cr. Net profit followed a similar trend, from Rs 19.98 Cr in Mar 2021 to Rs 9.33 Cr in Mar 2022, then increasing to Rs 14.17 Cr in Mar 2023, and falling to Rs 12.41 Cr in Mar 2025.
Profitability & returns
Tyche Industries Ltd. has an EPS of 6.77. The company's return on equity (ROE) is 493.9%, and its return on capital employed (ROCE) is 6.7378%. The profit margin for the company is 12.9%. Annual EPS has fluctuated, from 19.35 in Mar 2021 to 12.2 in Mar 2025.
Balance sheet
The debt-to-equity ratio for Tyche Industries Ltd. is 0, indicating the absence of debt. The book value per share is Rs 137.05. No other balance sheet specific figures are provided in the data.
Ownership & pledges
The public shareholding stands at 38.0342%. There is no promoter pledge reported (0%). The number of shareholders is 6786 as of June 2026.
Regulatory & surveillance
The company is not currently under any surveillance measure based on the provided data.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.